8-K: Shuttle Pharma Extends Interim CEO Cooper's Consulting Term

Shuttle Pharmaceuticals Holdings, Inc. has extended the consulting agreement for interim co-Chief Executive Officer Christopher Cooper through August 1, 2026.

Summary

• Shuttle Pharmaceuticals Holdings, Inc. (SHPH) entered into Amendment No. 1 to the Consulting Agreement with Number 2 Capital Corp., a Canadian entity owned by Christopher Cooper.
• The amendment, dated January 29, 2026, retroactively extends the term of the Consulting Agreement from September 11, 2025, to August 1, 2026.
• Christopher Cooper serves as the interim co-Chief Executive Officer of Shuttle Pharmaceuticals Holdings, Inc.
• Under the agreement, Number 2 Capital Corp. will continue to receive compensation of $20,000 per month for Mr. Cooper's services.
• Mr. Cooper is expected to work 40 hours per week and is subject to standard confidentiality and non-disclosure provisions.
• The agreement can be terminated by either party with 30 days' notice or immediately for cause.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While it provides leadership continuity, it also highlights the ongoing interim status of a key executive, which could be interpreted as a lack of long-term strategic clarity or a prolonged search for permanent leadership.

Positives

• Ensures continuity of leadership with interim co-CEO Christopher Cooper through August 1, 2026.

Negatives

• Continued reliance on an interim co-CEO and a consulting arrangement rather than a permanent executive appointment could signal uncertainty or a prolonged search for a permanent leader.
• The compensation of $20,000 per month for an interim role, while not inherently negative, represents a fixed cost for an extended period.

Risks

• Leadership Transition Risk: The continued interim status of the co-CEO suggests ongoing uncertainty regarding permanent leadership, which could impact long-term strategic planning and investor confidence.
• Key Person Dependence: Reliance on a single individual (Christopher Cooper) through a consulting firm for a critical executive role introduces key person risk.
• Contractual Termination Risk: The agreement can be terminated with 30 days' notice, potentially leading to an abrupt leadership change if either party exercises this right.

Future Outlook

The filing extends the term of the interim co-CEO's consulting agreement, providing continuity in leadership through August 1, 2026. This suggests the company anticipates Mr. Cooper's services will be required for at least this period, but does not provide further strategic or operational guidance.

Management Comments

• The Company and the Consultant desire to amend the Consulting Agreement to extend its term.

Industry Context

StockSavvy.ai notes that in the biotechnology and pharmaceutical sectors, leadership stability is crucial, especially for smaller companies like Shuttle Pharmaceuticals Holdings, Inc. The extension of an interim CEO's contract, while providing continuity, can also signal challenges in securing permanent leadership or a strategic decision to maintain flexibility during a critical development phase. This contrasts with larger, more established firms that typically have clear succession plans.

Comparison to Industry Standards

• The use of an interim CEO for an extended period is not uncommon in early-stage biotech companies, particularly those navigating clinical trials or seeking strategic partnerships, where flexibility in leadership structure can be advantageous.
• Compensation of $20,000 per month for an interim CEO role, equating to $240,000 annually, falls within a reasonable range for a small-cap biotech company, though it is on the lower end compared to permanent CEO salaries at more mature companies like Moderna or BioNTech, which can exceed several million dollars annually in salary, bonus, and equity.
• The 40-hour per week expectation is standard for a full-time executive role, even if structured as a consulting arrangement.

Management Changes

Corporate Governance

Related Party Transactions

• The Company entered into an amendment to a consulting agreement with Number 2 Capital Corp., an entity owned by Christopher Cooper, who also serves as the Company's interim co-Chief Executive Officer. This constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Provides clarity on interim leadership stability for the near term but may raise questions about the long-term executive search strategy.
• Employees: Ensures continuity in executive leadership, potentially reducing uncertainty within the organization.

Next Steps

• The Consulting Agreement will continue until August 1, 2026, unless terminated earlier.

Key Dates

Recommendation

This filing is a routine administrative update regarding an executive's contract extension and does not contain information that would fundamentally alter the company's financial prospects or strategic direction. It provides continuity in interim leadership but does not introduce new catalysts for significant share price movement. Investors should hold their positions and await more substantive operational or financial news.

Keywords

Shuttle Pharmaceuticals, SHPH, Christopher Cooper, Interim CEO, Consulting Agreement, Executive Compensation, Corporate Governance, SEC Filing, 8-K, Biotechnology, Pharmaceuticals